Pramipexole log
-
Day 0:
I tried ~0.5mL (1mg) about 30 minutes ago. Nothing interesting to report yet.
-
Update:
After taking a 2 hour nap (I didn't get much sleep) I vomited in the toilet, but at least I hadn't eaten anything for 5 hours. Clearly there's something in the bottle's clear liquid! Aside from the vomiting and POSSIBLY the sleepiness, I'm feeling absolutely nada.
Tomorrow I'm going to tone things down with 0.125mg or 0.25mg instead of 1mg.
-
@engineer 1mg was not a microdose, I was gonna mention XD
-
Last update for today:
I'm not feeling "high dopamine" symptoms. All the pramipexole seems to be doing is making me sleepy and nauseous.
@alfredoolivas is this supposed to happen with DAs?
-
@engineer The high dopamine state usually occurs with high noradrenaline, as well as a rise in serotonin that concurs with endogenous rises of dopamine and from drugs like cocaine.
-
@engineer Nausea happens from DA agonists too. I don't know why. D2 antagonists can reduce nausea.
-
By inhibiting endogenous dopamine production via D2 agonsim, it reduces dopamines downstream conversion into noradrenaline & adrenaline, making you tired
-
@alfredoolivas said in Pramipexole log:
By inhibiting endogenous dopamine production via D2 agonsim, it reduces dopamines downstream conversion into noradrenaline & adrenaline, making you tired
Could this still happen with a microdose like 0.125mg? If it does then seems like the DAs are pretty terrible and bromantane/selegiline is the only real option.
-
@engineer with that dose less so. Other DA agonists such as cabergoline can increase NA. Bromocriptine lowers it.
Some love them, others get no effect from them. I did get cool results from caber, it was euphoric at the start, it just made me insulin resistant. That could be why you feel tired too from a 1mg dose of prami which is quite high.
-
@alfredoolivas I asked AI about this and don't like what it said:
From a pharmacological and clinical research perspective, administering pramipexole at 0.125 mg/day occupies an interesting physiological space.
To provide accurate context, it is worth noting that while 0.125 mg/day is a very small amount, it is not strictly a "microdose" in the sense of being sub-therapeutic. It is the standard, commercially available starting dose for clinical titration (used to mitigate side effects like severe nausea and orthostatic hypotension) and is actively used as a therapeutic maintenance dose for mild Restless Legs Syndrome (RLS).
However, because pramipexole exhibits a biphasic, dose-dependent mechanism of action, a dose of 0.125 mg/day yields highly specific neurochemical effects that differ drastically from the higher doses (1.5 mg to 4.5 mg/day) used to treat Parkinson's disease.
Here is a breakdown of the possible effects and mechanisms of action at this specific dosage:
- The Presynaptic Autoreceptor Effect
Pramipexole is a non-ergoline dopamine agonist with a highly selective affinity for the D2 receptor subfamily, specifically demonstrating a 7- to 10-fold greater affinity for D3 receptors over D2 receptors.
At a low dose of 0.125 mg, pramipexole preferentially targets presynaptic autoreceptors rather than postsynaptic receptors.
Negative Feedback Loop: By stimulating these presynaptic autoreceptors, the drug tricks the brain into registering an abundance of dopamine. In response, the brain downregulates the endogenous synthesis and synaptic release of dopamine.
Transient Hypodopaminergic State: Paradoxically, administering this low dose of a dopamine agonist can temporarily decrease overall dopaminergic tone. In animal models, low doses of pramipexole are frequently associated with transient locomotor hypoactivity and sedation.
- Autoreceptor Desensitization (Chronic Administration)
If the 0.125 mg/day dose is sustained over a prolonged period, researchers observe a shift in neuropharmacodynamics.
Receptor Downregulation: Chronic stimulation desensitizes the somatodendritic D2 and D3 autoreceptors.
Neurotransmitter Rebound: Once these inhibitory autoreceptors desensitize, the firing rate of dopaminergic neurons normalizes or increases. Research also indicates this allows for a normalization of 5-HT1A (serotonin) autoreceptors, leading to a net enhancement in both dopamine and serotonin neurotransmission in the forebrain. This mechanism is the primary hypothesis for pramipexole's off-label efficacy in treating treatment-resistant and bipolar depression.
- Behavioral and Cognitive Processing
Because D3 receptors are heavily concentrated in the mesolimbic pathways (which govern mood, reward, and behavior) rather than the striatum (which governs motor control), low-dose pramipexole significantly impacts emotional and reward processing.
Blunted Reward Processing: Acute low doses have been shown in human fMRI studies to diminish the neural response to both rewarding and aversive stimuli in the ventromedial prefrontal cortex and striatum.
Impulse Control: While severe impulse control disorders (compulsive gambling, hypersexuality, overeating) are heavily correlated with the higher doses used in Parkinson's, the intense D3-binding profile of pramipexole means researchers still monitor for mild shifts in impulsivity and motivation even at 0.125 mg.
-
Physiological and Motor Effects
Motor Control: At 0.125 mg/day, the dose is generally sub-therapeutic for restoring significant motor function in Parkinson's disease, as it does not adequately occupy the postsynaptic D2 receptors in the striatum. However, it is often highly effective for restoring the descending dopaminergic inhibitory pathways in the spinal cord that alleviate RLS.
Adverse Effects: Even at this lowest clinical dose, a drug-naive subject may experience nausea (due to dopamine receptors in the chemoreceptor trigger zone), somnolence or sudden "sleep attacks," and mild orthostatic hypotension.
It would be terrible to have bottles of pramipexole laying around doing nothing, unless Gemini is wrong here?
